Repligen | RGEN - Operating Expenses


Repligen reported $183M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
Agilent USD 1.44B 9M Mar/2026
Align Technology USD 864.87M 2.84M Jun/2026
Bio Techne USD 235.92M 5.5M Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Bruker USD 813.2M 87.7M Mar/2026
Charles River Laboratories USD 875.93M 42.48M Mar/2026
Danaher USD 52.58B 368M Jun/2026
Dentsply International USD 1.32B 895M Mar/2026
General Electric Aerospace USD 17.64B 417M Jun/2026
Henry Schein USD 3.17B 77M Mar/2026
Illumina USD 899M 47M Jun/2026
IQVIA Holdings USD 1.77B 4.45B Jun/2026
Mettler Toledo International USD 739.77M 26.57M Jun/2026
Myriad Genetics USD 212.8M 16.2M Dec/2025
OraSure Technologies USD 40.35M 2.45M Dec/2025
Pacific Biosciences Of California USD 97.83M 41.29M Dec/2025
Pfizer USD 85.19B 4.91B Jun/2026
Repligen USD 183M 8.72M Jun/2026
Revvity USD 628.34M 2.12M Mar/2026
Standard Biotools USD 30.56M 15.16M Mar/2026
Thermo Fisher Scientific USD 9.81B 716M Jun/2026
Waters USD 1.12B 457.15M Mar/2026
West Pharmaceutical Services USD 2.99B 200K Jun/2026